Do sodium glucose transporter-2 inhibitors reduce HbgA1c levels more than dipeptidyl peptidase-4 inhibitors?

2018 ◽  
Vol 21 (9) ◽  
pp. 87-88
Author(s):  
Stephen D. Cagle ◽  
Aarti Chopra
Keyword(s):  
Glucose Transporter ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Glucose Transporter 2 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals The residual cardiorenal risk in type 2 diabetes

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Dario Giugliano ◽  
Maria Ida Maiorino ◽  
Giuseppe Bellastella ◽  
Katherine Esposito
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Glucose Transporter ◽  
Major Adverse Cardiovascular Events ◽  
World Population ◽  
Dipeptidyl Peptidase 4 ◽  
Cardiovascular Outcome Trials ◽  
Glucose Transporter 2 ◽  
Dipeptidyl Peptidase 4 Inhibitors

AbstractIn this commentary, we introduce the concepts of removed and residual risks in conditioning thecardiorenal outlook of patients with type 2 diabetes (T2D). The removed cardiorenal risk represents the risk of progression of CV events (major adverse cardiovascular events, MACE; heart failure, HF) and diabetes kidney disease (DKD) taken away by optimal glycemic control or the use of newer antihyperglycemic drugs (glucagon-like peptide-1 receptor agonists, GLP-1RA, andsodium-glucose transporter-2 inhibitors, SGLT-2i) in patients with T2D, as demonstrated by the results of intensive glucose lowering trials (IGT) and cardiovascular outcome trials (CVOT). IGT have shown that successful glycemic control has modest benefits, as the removed cardiorenal risk ranges from 9% for MACE, to 20% for progression of DKD and to 0% for HF. The removed risk of MACE is 13% for GLP-1RA and 12% for SGLT-2i. However, SGLT-2i, as compared with GLP-1RA, removed twofold more risk (39% vs 17%) for kidney outcomes and fourfold more risk (33% vs 9%) for HF. Dipeptidyl peptidase-4 inhibitors have no clinically important cardiorenal benefits, as residual risk is 99% for MACE, 100% for kidney outcomes (excluding new albuminuria), and 100% for HF. Although the results of some real world, population-based cohort studies suggest the possibility that the cardiorenal protection afforded by newer antihyperglycemic drugs is additive to that of optimal glycemic control, only specific randomized controlled trials could answer this question.

Impact of Switching from Sulfonylureas to Dipeptidyl Peptidase-4 Inhibitors on Hypoglycemia Burden in the United States—A Predictive Modeling Approach

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 385-P
Author(s):  
JINAN LIU ◽  
YUEXIN TANG ◽  
HAKIMA HANNACHI ◽  
SAMUEL S. ENGEL ◽  
SWAPNIL RAJPATHAK
Keyword(s):  
United States ◽  
Predictive Modeling ◽  
The United States ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Modeling Approach ◽  
Dipeptidyl Peptidase 4 Inhibitors

An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors

2012 ◽  
Vol 8 (3) ◽  
pp. 169-182 ◽  
Author(s):  
Brian K. Irons ◽  
Jessica M. Weis ◽  
Megan R. Stapleton ◽  
Krystal L. Edwards
Keyword(s):  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Vaia Lambadiari ◽  
Aikaterini Kountouri ◽  
Foteini Kousathana ◽  
Emmanouil Korakas ◽  
Georgios Kokkalis ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Prospective Observational Study ◽  
Dipeptidyl Peptidase ◽  
Dermatology Department ◽  
Steroid Administration ◽  
Dipeptidyl Peptidase 4 ◽  
Increased Risk ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
A Prospective Study

Abstract Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. The objective of our study was to prospectively estimate the association between gliptins and the development of bullous pemphigoid. Methods We conducted a prospective study which included all patients diagnosed with biopsy-proven bullous pemphigoid in the Dermatology Department of our hospital between April 1, 2009 and December 31,2019. The diagnosis of bullous pemphigoid was based on specific clinical, histological and immunological features. Results Overall 113 consecutive patients (age 75 ± 13 years, 62 females) with the diagnosis of bullous pemphigoid were enrolled. Seventy-six patients (67.3%) suffered from type 2 Diabetes and 52 (46%) were treated with dipeptidyl-peptidase 4 inhibitors. The most frequent prescribed gliptin was vildagliptin, being administered to 45 cases (39.8% of total patients enrolled, 86.5% of the patients treated with gliptins). Gliptins were withdrawn immediately after the diagnosis of bullous pemphigoid, which together with steroid administration led to remission of the rash. Conclusions This study revealed that treatment with dipeptidyl-peptidase 4 inhibitors, especially vildagliptin, is significantly associated with an increased risk of bullous pemphigoid development.

In vitrometabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223

Xenobiotica ◽  
2011 ◽  
Vol 41 (6) ◽  
pp. 445-455 ◽  
Author(s):  
Hee Jeong Ahn ◽  
Kwon-Bok Kim ◽  
Kwang-Hyeon Liu ◽  
Jae-Gook Shin ◽  
Jin Hee Ahn ◽  
...  
Keyword(s):  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document